US · Healthcare · Biotechnology
EPS came in at 0.16 against a street estimate of 0.16 — a beat of 0.0%.
Analysts rate ADMA Biologics Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $17.00.
CONFIDENT ASCENIV accelerating with 24% YoY growth and strongest monthly gains since H1 2024; BIVIGAM stabilizing despite competitive pressure. Reiterating full-year guidance. Real-world evidence expanding payer confidence. Q2 2026 Call focused on U.S. immunoglobulin market. McKesson partnership expanding access through GPO buying groups in secondary immunodeficiency, non-overlapping with legacy ASCENIV call points. Analysts probed McKesson GPO overlap and payment terms (none), BIVIGAM recovery timeline (none expected soon), and secondary immunodeficiency expansion (ongoing investigator studies but primary IG focus nearer-term). Management defensive on BIVIGAM but bullish on ASCENIV runway. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 16.44% |
| State Street Corp | 6.29% |
| Vanguard Capital Management, LLC | 4.60% |
| Vanguard Portfolio Management, LLC | 3.96% |
| Capital Research Global Investors | 3.91% |
| First Trust Advisors L.P. | 3.48% |
| Nuveen, LLC | 2.72% |
| Geode Capital Management, LLC | 2.60% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 ADMA BIOLOGICS, INC. — FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Net Income (6 months): $83,150 thousand ($83.2 million) | 2026-08-05 |
| Results announced · Q3 2026 ADMA BIOLOGICS INC. – Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenue: $124.4 million, up 2% year-over-year (vs. $122.0 m | 2026-08-05 |
| Shareholder vote results · Q2 2026 ADMA BIOLOGICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 2, 2026 • 232,324,283 shares outstanding as of April 8, 2026 (record | 2026-06-02 |
| Quarterly report · Q1 2026 ADMA BIOLOGICS, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Quarterly Revenue: $114.5 million (Q1 2026) vs. $114.8 million (Q1 2025) – essentiall | 2026-05-06 |
| Results announced · Q2 2026 ADMA BIOLOGICS – 1Q 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • 1Q 2026 Total Revenue: $114.5 million, essentially flat vs. $114.8 million in 1Q 2025 | 2026-05-06 |
| Company announcement · Q2 2026 ADMA BIOLOGICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Announcement Date: May 4, 2026 • Company: ADMA Biologics, Inc. (Nasdaq: ADMA) • Headquart | 2026-05-04 |
| Proxy statement · Q2 2026 ADMA BIOLOGICS, INC. — 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 (Director Election): Elect two Class I directors to | 2026-04-15 |
| Annual report FY2025 ADMA BIOLOGICS, INC. – FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market capitalization (as of June 30, 2025): $4,229,956,395 based o | 2026-02-25 |
Readable in the app.
| Announcement | Date |
|---|---|
| Accelerated share repurchase agreement for $125 million announced ADMA Biologics announced on March 2, 2026, that it entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank to buy back $125 million of its own stock. This is pa | 2026-03-02 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ADMA Biologics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.